Across TCGA pan-cancer cohorts, MRPL53 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRPL53 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MRPL53 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL53 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, OV, and LIHC are the cancer types where MRPL53 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.081	0.768	<.001	48	view →
OV	OS	Median	II,III,IV	0.176	0.846	<.001	36	view →
LIHC	DFS	Median	All	0.079	0.544	<.001	24	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	All	1.000	0.614	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MRPL53 tumor-vs-normal RNA expression · all MRPL53 data types